Tarsus Pharmaceuticals (TARS) EBT (2019 - 2026)

Tarsus Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, EBT rose 81.92% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at -$146.5 million (down 42.43% YoY), while the FY2025 annual figure was -$64.4 million, up 44.3% from the prior year.
• EBT for Q1 2026 stood at -$4.5 million, up from -$5.6 million in the prior quarter.
• The five-year high for EBT was -$4.5 million in Q1 2026, with the low at -$123.7 million in Q2 2025.
• The 5-year median for EBT is -$23.3 million (2023), against an average of -$28.4 million.
• The sharpest annual moves came in 2023 and 2026: EBT sank 474.12% in 2023, then soared 81.92% in 2026.
• Tarsus Pharmaceuticals' EBT stood at -$13.6 million in 2022, then sank by 210.57% to -$42.3 million in 2023, then surged by 45.45% to -$23.1 million in 2024, then jumped by 75.54% to -$5.6 million in 2025, then increased by 19.82% to -$4.5 million in 2026.
• Business Quant data shows TARS's EBT at -$4.5 million in Q1 2026, -$5.6 million in Q4 2025, and -$12.7 million in Q3 2025.